Core Viewpoint - China General Nuclear Power Technology Co., Ltd. (CGN Tech) is a leading enterprise in non-power nuclear technology, focusing on accelerator manufacturing and irradiation processing services, with a strategic emphasis on its core business [1][5]. Financial Performance - For Q3 2025, CGN Tech reported revenue of 4.065 billion yuan, ranking 8th in the industry, significantly above the industry average of 1.994 billion yuan but far below the top competitor, Sinochem International, at 35.716 billion yuan [2]. - The company's net profit for the same period was -109 million yuan, placing it 74th in the industry, which is considerably lower than the industry average net profit of 74.438 million yuan [2]. - The main business composition includes new materials at 2.136 billion yuan (82.38%), with other segments contributing 220 million yuan (8.49%) and electronic accelerators and irradiation processing at 218 million yuan (8.40%) [2]. Financial Ratios - As of Q3 2025, CGN Tech's debt-to-asset ratio was 44.49%, down from 47.95% year-on-year, but still above the industry average of 34.74% [3]. - The gross profit margin for the same period was 13.47%, an increase from 12.50% year-on-year, yet still below the industry average of 19.93% [3]. Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 17.23% to 48,400, while the average number of circulating A-shares held per shareholder increased by 28.65% to 17,400 [5]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Southern CSI 1000 ETF, with notable changes in their holdings [5]. Business Highlights - CGN Tech is recognized as the only manufacturing champion in the domestic electronic accelerator sector, with a production capacity of 90 units per year and a 30% increase in accelerator sales expected in 2024 [6]. - The company is expanding its nuclear medicine sector with the proton therapy equipment and isotope production, with production expected to commence soon [5][6]. - Revenue projections for 2025 to 2027 are 6.760 billion yuan, 7.708 billion yuan, and 8.206 billion yuan, respectively, with net profits expected to rise from 55 million yuan in 2025 to 221 million yuan in 2027 [5][6].
中广核技的前世今生:技术派掌舵,新材料营收占比超八成,核医疗拓展可期